BioAtla, Inc.

BioAtla reported Q3 2025 net loss of $15.8 million versus a net loss of $10.6 million in Q3 2024. The year-ago quarter included $11 million in collaboration revenue from the Context license, while 2025 included a $2.1 million non-cash loss on warrant liability. R&D expense was $9.5 million, down from $16.4 million a year ago, and G&A was $4.2 million versus $5.9 million. Cash and cash equivalents were $8.3 million as of 09/30/2025, before the October $2 million Context milestone payment. On guidance, management said R&D should decline through the remainder of 2025, the OSV phase 3 study is expected to start early next year, the goal is to advance it with a strategic partner early next year, and BA 3182 data are expected in the first half of next year; the company also expects a key clinical trial readout in 2026 for the EpCAM program.

Jay Short framed the quarter as a transition point, emphasizing that BioAtla is in advanced stages of a strategic transaction with a potential partner by year-end. He highlighted FDA alignment on the OSV phase 3 design and said the dual-endpoint study could support accelerated approval followed by full approval. His tone was upbeat and opportunistic, repeatedly pointing to the platform’s validation, the Context milestone, and upcoming readouts as catalysts.

Richard Waldron said cash and cash equivalents were $8.3 million at 09/30/2025, and noted that the company received a $2 million Context milestone payment in October that was not included in quarter-end cash. He explained the Q3 net loss of $15.8 million versus $10.6 million last year, with the comparison affected by $11 million of collaboration revenue in the prior-year quarter and a $2.1 million non-cash warrant liability loss this year. He also cited lower spend: R&D fell to $9.5 million from $16.4 million, and G&A declined to $4.2 million from $5.9 million, with further R&D declines expected through the rest of 2025 as resources stay focused on prioritized programs.

On the OSV phase 3 design, an analyst asked about patient numbers for accelerated approval and stratification in the control arm. Eric Sievers said full approval would involve approximately 300 prospectively randomized and stratified patients, while accelerated approval would come from an interim analysis around the time of full enrollment; he said stratification factors were not fully disclosed, but P16 and local regional disease status would be among them. On BA 3182, management said the next update is expected in the first half of next year and will include broader dose and schedule evaluation data, with Jay Short adding they expect to meet that timeline.